Verrica Pharmaceuticals’ Ycanth (cantharidin) Topical Solution Receives the US FDA’s Approval for Pediatric and Adult Patients with Molluscum Contagiosum
Shots:
- The US FDA has approved Ycanth (cantharidin) topical solution for adult & pediatric patients aged ≥2yrs. with molluscum contagiosum. The approval was based on 2 P-III trials (CAMP-1 & 2) that evaluated VP-102 (Ycanth) vs PBO in patients aged ≥2yrs.
- Both trial results showed that patients treated with VP-102 met its 1EPs of complete clearance of all treatable molluscum lesions, 46% vs 18% achieved complete clearance of molluscum lesions in the (CAMP-1) trial while 54% vs 13% in the (CAMP-2) trial
- In an additional post-hoc analysis, complete clearance of all lesions was higher in the VP-102 group vs vehicle across all body regions. Ycanth, a drug-device combination product administered by a healthcare professional is expected to be available in Sept 2023
Ref: Globenewswire | Image: Merck
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
